<DOC>
	<DOCNO>NCT01199640</DOCNO>
	<brief_summary>This phase 2a study MLN1202 determine safety , tolerability initial efficacy patient relapsing-remitting multiple sclerosis ( RRMS ) . It conduct 2 dose cohort enrol total 50 patient . Efficacy assess compare number new gadolinium-enhancing brain lesion screen treatment period .</brief_summary>
	<brief_title>Study Safety Efficacy MLN1202 Patients Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Each patient meet follow inclusion criterion enrol study : 18 year age old Diagnosis relapsingremitting multiple sclerosis ( RRMS ) An Expanded Disability Status Score ( EDCC ) 0 5.5 , inclusive Be willing able comply protocol duration study period Be willing use adequate `` doublebarrier '' contraceptive method duration study period If female , must neither pregnant breastfeeding Written inform consent To enrol treatment phase study patient must total least 2 new gadoliniumdiethylenetriamine pentaacetic acid ( Gd ) enhance lesion see series 3 pretreatment magnetic resonance imaging ( MRI ) s. Patients meet follow exclusion criterion enrol study : Diagnosis primary progressive multiple sclerosis ( PPMS ) secondary progressive multiple sclerosis ( SPMS ) Received investigational drug experimental procedure within 3 month prior study day 0 If patient receive diseasemodifying treatment must discontinue prior study day 0 follow : 1 . Cyclophosphamide mitoxantrone 6 month prior 2 . Interferons , glatiramer acetate azathioprine 12 week prior 3 . Methotrexate , IV immunoglobulin , cyclosporin , plasma exchange corticosteroid 8 week prior Never expose Tysabri® ( natalizumab ) VLA4 ( α4β1 ) antagonist Have active infection consider high risk develop infection Have history hepatitis B , C human immunodeficiency virus ( HIV ) Have chest Xray within 6 month study day 0 clinically significant finding abnormality Have inadequate renal hepatic function Have know history cancer , except distant history ( &gt; 10 year ) carcinoma situ cervix adequately treat basal cell carcinoma skin Received live , attenuated vaccination within 30 day prior study day 0 Have history illicit drug alcohol abuse within 5 year study day 0 Have history hypersensitivity prior monoclonal antibody ( mAb ) treatment Have history allergy sensitivity Gd Have history would preclude serial MRI scan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>